More encouragingly, the FDA has approved a therapeutic prostate cancer vaccine which modified by fusion protein that combines recombinant prostate acid phosphatase (PAP) with recombinant GM-CSF called Sipuleucel-T in April 2010. This evidence concerns the gene ACP3 and Familial prostate cancer.